Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts $111.71 -3.74 (-3.24%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ligand Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataLGND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LGND Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Ligand Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241$0.75$0.75$0.75 Q2 20241$0.67$0.67$0.67 Q3 20241$0.80$0.80$0.80 Q4 20241$0.75$0.75$0.75 FY 20244$2.97$2.97$2.97 Q1 20251$0.98$0.98$0.98 Q2 20251$1.01$1.01$1.01 Q3 20251$1.00$1.00$1.00 20253$2.99$2.99$2.99 Q1 20261$1.19$1.19$1.19 Ligand Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 8/6/2024Q2 2024$1.06$1.40+$0.34$4.72$33.04M$41.50M 5/7/2024Q1 2024$0.83$3.84+$3.01-$3.15$27.92M$30.90M 2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54M$28.10M 11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22M$32.87M 8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74M$26.37M 5/4/2023Q1 2023$0.89$2.28+$1.39$1.59$33.55M$43.98M There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t2/22/2023Q4 2022$1.23$1.36+$0.13$0.52$39.63M$50.40M Ligand Pharmaceuticals Earnings - Frequently Asked Questions When is Ligand Pharmaceuticals's earnings date? Ligand Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on LGND's earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2024 earnings guidance on Thursday, November, 7th. The company provided earnings per share guidance of 5.500-5.700 for the period, compared to the consensus earnings per share estimate of 5.390. The company issued revenue guidance of $160.0 million-$165.0 million, compared to the consensus revenue estimate of $156.4 million. How much revenue does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $131.31 million. How much profit does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $52.15 million. LGND has generated $2.51 earnings per share over the last four quarters. What is Ligand Pharmaceuticals's price-to-earnings ratio? Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 44.51 and a forward price-to-earnings ratio of 32.19. What is Ligand Pharmaceuticals's EPS forecast for next year? Ligand Pharmaceuticals's earnings are expected to grow from $3.47 per share to $4.10 per share in the next year, which is a 18.16% increase. ` More Earnings Resources from MarketBeat Related Companies Nurix Therapeutics Earnings Praxis Precision Medicines Earnings Travere Therapeutics Earnings Arcturus Therapeutics Earnings COMPASS Pathways Earnings Shattuck Labs Earnings Repligen Earnings Halozyme Therapeutics Earnings Madrigal Pharmaceuticals Earnings Ionis Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t This page (NASDAQ:LGND) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this BEFORE November 19th.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Ligand Pharmaceuticals Incorporated You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LGND Stock Alerts